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Abstract 
While current literature provides evidence that imatinib mesylate has significant activity 
in patients with advanced and metastatic gastrointestinal stromal tumour (GIST), and 
highlights the potential for the development of anticancer drugs based on specific 
molecular abnormalities present in cancers, specific recommendations concerning the 
optimal duration of therapy remain controversial. This case presents the favourable 
outcome of a patient who originally presented almost 9 years ago with widespread, 
bulky, metastatic GIST involving the abdomen and pelvis. A sustained, complete 
response was achieved with imatinib and prompted an interruption in treatment 7 years 
after initial presentation. The disease reoccurred extensively within 9 months of 
treatment interruption, but once again rapidly completely responded to the 
recommencement of imatinib, with that response being now maintained for over 9 
months. This report suggests that dramatic and durable responses to imatinib can be 
achieved in individual cases despite the lack of specific guidelines in the literature with 
respect to defining how long treatment with imatinib should be continued in the 
absence of evidence of tumour progression. 
 
Introduction 
Gastrointestinal stromal tumours (GISTs) are uncommon neoplasms representing 
<3% of all gastrointestinal malignancies and accounting for 80% of gastrointestinal 
mesenchymal tumours [1]. These rare tumours have an estimated incidence of 1.5 cases 
per 100,000 persons [2]. GISTs are mostly seen in the gastrointestinal tract, mainly in the 
fundus of the stomach (60–70%) or the small intestine (25–35%), and less commonly in 
the rectum, oesophagus or colon. However, sporadic primary GISTs arising at sites  
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unrelated to the tubular gastrointestinal tract have been reported [3, 4]. Additionally, the 
management of GISTs has benefitted from the development of anticancer drugs based on 
specific molecular abnormalities present in cancers. 90% of GISTs express the c-KIT 
(CD117) protein, the primary target of the targeted therapeutic agent imatinib mesylate. 
The introduction of imatinib following surgical resection has markedly improved 
outcomes in this rare condition. 
Case Report 
We report here the case of a 54-year-old male, diagnosed with extensive metastatic GIST, following 
presentation in June 2002 with left flank pain, anorexia and weight loss of 5 kg over 4 weeks. An initial 
abdominal examination revealed a large, tender, intra-abdominal mass arising from his left 
hypochondrium. Laboratory studies, including blood biochemistry and CEA/CA19.9 tumour markers, 
were within the normal range and a chest X-ray was also negative.  
The subsequent contrast spiral computed tomography (CT) scan of the abdomen and pelvis revealed 
a lobulated, heterogeneous, low-attenuated mass in the left upper abdomen extending from the left 
hemi-diaphragm to the lower abdomen anterior to the left kidney (fig. 1). The mass measured 
approximately 180 × 160 × 90 mm and extended to the left lobe of the liver, the lateral wall of the 
stomach and anterior border of the spleen. A similar lesion was noted in the lower pelvis, posterior to 
the bladder, measuring 90 × 80 × 87 mm. A third lesion in the mid upper pelvic region measured about 
35 mm in diameter. No abnormalities were detected in the liver, pancreas, spleen, adrenal glands or 
kidney. 
The patient proceeded to laparotomy at which time the tumour was debulked. Tumour infiltration 
was noted to be complex, extending from the epigastrium to the pelvis and involving the spleen, greater 
curvature of the stomach, mesentery and peritoneal cavity. A post-operative CT scan reported evidence 
of residual tumour within the omentum, mesentery, pelvis and remaining stomach, measuring 100 mm 
in its longest superior-inferior perpendicular diameter and 85 mm in the longest cross-sectional 
perpendicular diameter. The patient’s post-operative course was complicated by persistent left flank 
pain and intermittent nausea. 
Histopathological examination of the resected tumour confirmed a malignant GIST primarily 
arising from the stomach wall. Immunohistochemical analysis showed the following 
immunophenotype: smooth muscle actin (SMA) negative, desmin negative, S100 negative, MNF 116 
(broad-spectrum cytokeratin) positive, CD34 positive and c-KIT (CD117) positive.  
In view of the presence of extensive residual tumour despite surgical debulking, the patient was 
commenced on a course of imatinib mesylate. The initial prescribed dose was 400 mg b.i.d. based on 
evidence from the phase I study by van Oosterom et al. [5]. No evidence of residual disease was noted 
on CT scan 2 months following the commencement of imatinib. The patient continued to tolerate 
imatinib well, reporting only an intermittent itch and persistent nausea which was adequately treated 
with ondansetron 8 mg b.i.d. Three-monthly clinical reviews continued and radiological follow-ups 
were unremarkable, confirming an excellent complete clinical response to treatment. Due to the lack of 
evidence in the published literature regarding the ongoing use of imatinib in the treatment of metastatic 
GIST once a cytogenic response has been achieved, the patient was continued on imatinib indefinitely. 
In June 2003, the patient’s imatinib dosage was changed to 600 mg daily, in line with contemporary 
treatment guidelines. 
Imatinib therapy was ceased some 7 years after its commencement in August 2009, when the patient 
underwent a left radical nephrectomy to remove an unrelated, localised, 42-mm, grade II, renal cell 
carcinoma involving the upper pole of the left kidney. Imatinib was discontinued at that time due to the 
patient’s slow post-surgical recovery. No evidence of disease recurrence was evident on follow-up CT 
imaging.  
Approximately 9 months after ceasing imatinib therapy, the patient presented with an exacerbation 
of severe abdominal pain. The pain had been present over the preceding 2 weeks and was associated 
with significant nausea, vomiting, tiredness and lethargy. A CT scan conducted in May 2010 revealed 
multiple solid masses within the abdomen and pelvis with the largest mass in the lower abdomen/pelvis,  
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measuring 11 × 11 cm (fig. 2, arrows). The lesions were noted to involve the left and right subphrenic 
spaces, the subcapsular surface of the inferolateral aspect of the liver, the gastro-hepatic ligament region 
and the left rectus sheath with extension into the underlying peritoneum. Additionally, there was also 
evidence of gross tumour within the left para-aortic region of the peritoneum and the lower abdomen 
and pelvis. A CT-guided core biopsy and subsequent histopathological examination of the tumour 
confirmed recurrent metastatic GIST with immunostains being positive for CD117 and negative for 
SMA, desmin and S100.  
In view of the diagnosis of recurrent disease, the patient was recommenced on imatinib 600 mg 
daily. Upon review 2 weeks after the recommencement of therapy, the patient’s gross abdominal 
distension had markedly decreased as had his abdominal pain and nausea. A CT scan, performed 6 
weeks after the recommencement of imatinib, reported very little evidence of residual malignancy. This 
patient continues on imatinib 600 mg daily with an excellent sustained clinical response. Serial CT scans 
confirm a complete response to the reintroduction of imatinib now at 9 months from the time of 
recurrence. Unfortunately, his ongoing treatment is complicated by persistent nausea. 
Discussion 
This case presents the favourable outcome of a patient who originally presented almost 
9 years ago with widespread, bulky, metastatic GIST involving the abdomen and pelvis. A 
sustained complete response was achieved with imatinib and prompted an interruption in 
treatment 7 years after initial presentation. The disease reoccurred extensively within 9 
months of treatment interruption but once again rapidly completely responded to the 
recommencement of imatinib.  
Whereas a decade ago there was no effective systemic therapy available for advanced 
GIST, the introduction of imatinib, a potent tyrosine kinase inhibitor selectively blocking 
KIT and PDGFR, into clinical practice has dramatically improved the outcome of patients 
with advanced GIST. Accordingly, imatinib is now the treatment of choice for c-KIT-
positive, unresectable and/or metastatic malignant GIST, and for adjuvant treatment for 
adult patients following resection of c-KIT-positive GIST. 
While imatinib has become standard treatment for patients with advanced GIST, it is 
not known whether imatinib can be stopped in patients in whom disease is controlled. 
Scientific evidence in this area is scarce and no specific recommendations can as yet be 
made in regards to the optimal duration of imatinib treatment in the setting of advanced 
or metastatic GIST. Some studies have reported that imatinib interruption results in rapid 
progression in most patients with advanced GIST, and cannot be recommended in 
routine practice unless the patient experiences significant toxicity [6]. This observation 
was further confirmed in patients who were subsequently randomised in this study after 3 
years of imatinib therapy [7]. Findings from a long-term analysis of a randomised phase 
II trial of standard versus higher dose imatinib for patients with unresectable or 
metastatic GIST reported that nearly 50% of patients with advanced disease treated with 
imatinib survived for more than 5 years irrespective of their starting dose [8]. 
In terms of clinical outcomes following the discontinuation or interruption of imatinib 
in the treatment of GIST, some clinical trials show promising results. The most 
informative data in relation to stopping imatinib for a patient who commenced imatinib 
for metastatic GIST and subsequently achieved a complete response comes from the BFR-
14 trial conducted by the French Sarcoma Group. In this study, patients exhibiting either 
a complete response, partial response or with stable disease were randomised after 1, 3 or 
5 years of continuous imatinib to either continue taking imatinib or to stop this  
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intervention. The results for patients who were randomised after 1 year of imatinib were 
published in 2007 and confirmed that progression-free survival of patients with complete 
response was not significantly different from that of patients with residual tumour in the 
group who stopped imatinib, with a high risk of relapse even in patients with complete 
response on CT scan [6]. 
Blay et al. [6] conducted a prospective, randomised, multicentre, phase III trial 
comparing interrupted versus continuous treatment of imatinib in 182 patients with 
advanced GIST beyond 1 year. 31% of patients treated with continuous imatinib had 
documented disease progression compared to 81% in the interrupted imatinib group (p < 
0.0001). The results demonstrated that imatinib treatment interruption resulted in rapid 
disease progression compared to the patient group receiving continuous treatment. The 
authors therefore concluded that treatment interruption resulted in rapid progression in 
most patients with advanced GIST and therefore should not be recommended in standard 
practice unless the patient experienced significant toxicity.  
An update of the BFR-14 trial at a median follow-up of 37 months showed that 91% of 
patients in the interrupted arm versus 62% in the continuous arm experienced 
progressive disease (p < 0.0001). 92% of patients in the interrupted arm achieved tumour 
control once they recommenced imatinib after first progression. The authors concluded 
that the reintroduction of imatinib allowed for tumour control in the majority of patients, 
no unfavourable impact of imatinib interruption on overall survival was noted, and 
treatment interruption could be a therapeutic option in advanced GIST patients 
exhibiting intolerance to imatinib [9]. 
Moreover, Adenis et al. [10] reported that the majority of patient’s responding to 
imatinib treatment relapsed when imatinib was ceased after 3 years of treatment. 
However, the study findings also concluded that the GIST cells remained sensitive to 
imatinib during treatment reintroduction. Additionally, imatinib reintroduction at the 
same dose resulted in tumour control in the majority of patients [11]. Similar results were 
also observed for those patients who were randomised after 5 years of imatinib. Ray-
Coquard et al. [12] have reported that stopping imatinib after 5 years resulted in a higher 
rate of disease progression than imatinib maintenance in patients with advanced GIST 
responding to or stabilised by imatinib.  
Lee et al. [13] conducted a prospective study to evaluate the clinical outcome of 
imatinib interruption in GIST patients who had achieved stable disease or showed better 
response to imatinib therapy. Following imatinib reintroduction in the interrupted group, 
88% of patients achieved disease control. There were no statistically significant differences 
in imatinib refractory progression-free survival and overall survival between the groups. 
The authors concluded that imatinib may be interrupted at least temporarily, in patients 
with GIST controlled with imatinib when various clinical situations limit continuous 
treatment. 
Several problems may be associated with long-term administration of imatinib [6]. 
Specifically, patients may experience severe adverse effects requiring treatment 
interruption. Secondly, patients may not tolerate chronic adverse effects and may request 
treatment interruption, as occurred in this case. Some series have shown that resistance to 
imatinib occurs at a median of 24 months and happens in a substantial proportion of 
patients by 4 years. Such resistance can be related to alteration of pharmacokinetics with  
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prolonged exposure, and acquisition of additional mutations in the KIT gene, resulting in 
imatinib-resistant KIT proteins. 
Conclusion 
The limited current evidence would suggest that imatinib needs to be given 
continuously until disease progression or intolerance in the population of non-
progressive advanced or metastatic GIST patients. The evidence also suggests that the 
reintroduction of imatinib can re-establish tumour control in most, but not all patients. 
However, no differences in the incidence of secondary resistance to imatinib or in overall 
survival have been observed so far. Notwithstanding this, dramatic and sustained 
responses can be achieved with imatinib in individual cases, as was found in the case 
reported. 
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Fig. 1. Abdominal CT finding: CT scan performed in 2002 at the time of the original diagnosis of GIST 
showing a lobulated, heterogeneous, low-attenuated mass in the left upper abdomen extending from 
the left hemi-diaphragm to the lower abdomen anterior to the left kidney. 
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Fig. 2. Serial CT scan images of the patient. a Follow-up CT scan showing no evidence of disease 6 
months after cessation of imatinib and 3 months before recurrence was confirmed; b CT scan 
performed at the time of disease recurrence showing extensive tumour involving the left subphrenic 
space; c CT scan 6 months after recommencement of imatinib showing no residual disease. 
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